123 related articles for article (PubMed ID: 20599875)
1. Development of an Abbott ARCHITECT cyclosporine immunoassay without metabolite cross-reactivity.
Brate EM; Finley DM; Grote J; Holets-McCormack S; Ozaeta PF; Pacenti D; Peart JE; Piktel RE; Ramsay CS; Rupprecht KR; Saldana SC; Spring TG; Tetin SY; Trudeau BC; Wang P; Xie H
Clin Biochem; 2010 Sep; 43(13-14):1152-7. PubMed ID: 20599875
[TBL] [Abstract][Full Text] [Related]
2. Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay.
Wallemacq P; Maine GT; Berg K; Rosiere T; Marquet P; Aimo G; Mengozzi G; Young J; Wonigeit K; Kretschmer R; Wermuth B; Schmid RW
Ther Drug Monit; 2010 Apr; 32(2):145-51. PubMed ID: 20216110
[TBL] [Abstract][Full Text] [Related]
3. Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer.
Schmid RW; Lotz J; Schweigert R; Lackner K; Aimo G; Friese J; Rosiere T; Dickson D; Kenney D; Maine GT
Clin Biochem; 2009 Oct; 42(15):1543-8. PubMed ID: 19563794
[TBL] [Abstract][Full Text] [Related]
4. Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay.
Coentrão L; Carvalho C; Sampaio S; Oliveira JG; Pestana MI
Transplant Proc; 2010 Jun; 42(5):1867-9. PubMed ID: 20620539
[TBL] [Abstract][Full Text] [Related]
5. Detection of antibodies to hepatitis C virus: false-negative results in an automated chemiluminescent microparticle immunoassay (ARCHITECT Anti-HCV) compared to a microparticle enzyme immunoassay (AxSYM HCV Version 3.0).
Myrmel H; Navaratnam V; Asjø B
J Clin Virol; 2005 Nov; 34(3):211-5; discussion 216-8. PubMed ID: 16112611
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine metabolite cross-reactivity in different cyclosporine assays.
Murthy JN; Yatscoff RW; Soldin SJ
Clin Biochem; 1998 Apr; 31(3):159-63. PubMed ID: 9629489
[TBL] [Abstract][Full Text] [Related]
7. [Hepatitis C virus screening: performances characteristics of a commercial automated chemiluminescent microparticle immunoassay (CMIA-ARCHITECT anti-HCV)].
Petitjean Lecherbonnier J; Gouarin S; Dina J; Vabret A; Freymuth F
Pathol Biol (Paris); 2007 Dec; 55(10):512-20. PubMed ID: 17959324
[TBL] [Abstract][Full Text] [Related]
8. Competitive immunoassay for cyclosporine using capillary electrophoresis with laser induced fluorescence polarization detection.
Ye L; Le XC; Xing JZ; Ma M; Yatscoff R
J Chromatogr B Biomed Sci Appl; 1998 Aug; 714(1):59-67. PubMed ID: 9746235
[TBL] [Abstract][Full Text] [Related]
9. Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study.
Soldin SJ; Steele BW; Witte DL; Wang E; Elin RJ;
Arch Pathol Lab Med; 2003 Jan; 127(1):19-22. PubMed ID: 12521361
[TBL] [Abstract][Full Text] [Related]
10. Analytical performance of the CEDIA cyclosporine PLUS whole blood immunoassay.
Butch AW; Fukuchi AM
J Anal Toxicol; 2004 Apr; 28(3):204-10. PubMed ID: 15107152
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a chemiluminescent microparticle immunoassay for determination of Treponema pallidum antibodies.
Yoshioka N; Deguchi M; Kagita M; Kita M; Watanabe M; Asari S; Iwatani Y
Clin Lab; 2007; 53(9-12):597-603. PubMed ID: 18257467
[TBL] [Abstract][Full Text] [Related]
12. Variability in telavancin cross-reactivity among vancomycin immunoassays.
McConeghy KW; Liao S; Clark D; Worboys P; Barriere SL; Rodvold KA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7093-7. PubMed ID: 25223996
[TBL] [Abstract][Full Text] [Related]
13. The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation.
Stephens E; Bolderson I; Clark B; Kinsey S; Gooi HC; Cook G
Ann Clin Biochem; 2006 Sep; 43(Pt 5):382-8. PubMed ID: 17022881
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cyclosporine concentrations in renal transplant recipients using ACMIA and mFPIA methods.
Kagawa Y; Yanagawa M; Muraki Y; Iwamoto T; Mizutani H; Sugimura Y; Kojima M
Clin Biochem; 2004 Nov; 37(11):1016-21. PubMed ID: 15498531
[TBL] [Abstract][Full Text] [Related]
15. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific?
Steimer W
Clin Chem; 1999 Mar; 45(3):371-81. PubMed ID: 10053038
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods.
Hamwi A; Salomon A; Steinbrugger R; Fritzer-Szekeres M; Jäger W; Szekeres T
Am J Clin Pathol; 2000 Oct; 114(4):536-43. PubMed ID: 11026099
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation.
Cattaneo D; Zenoni S; Murgia S; Merlini S; Baldelli S; Perico N; Gotti E; Ottomano C; Crippa A; Remuzzi G
Clin Chim Acta; 2005 May; 355(1-2):153-64. PubMed ID: 15820490
[TBL] [Abstract][Full Text] [Related]
18. [Immunoanalytical methods of cyclosporine A determination].
Safarcík K; Komzáková I; Bartos V; Grundmann M
Ceska Slov Farm; 2002 May; 51(3):112-20. PubMed ID: 12058351
[TBL] [Abstract][Full Text] [Related]
19. Interference of oleandrin and oleandrigenin in digitoxin immunoassays: minimal cross reactivity with a new monoclonal chemiluminescent assay and high cross reactivity with the fluorescence polarization assay.
Datta P; Dasgupta A
Ther Drug Monit; 1997 Aug; 19(4):465-9. PubMed ID: 9263390
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactivities of cyclosporin G (NVa2 cyclosporin) and metabolites in cyclosporin A immunoassays.
Yatscoff RW; Langman LJ; LeGatt DF
Clin Chem; 1993 Jun; 39(6):1089-92. PubMed ID: 8504544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
